QUOTE AND NEWS
Benzinga  Nov 18  Comment 
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported on Tuesday it expects its fiscal 2015 earnings per share to be in a range of $2.14 to $2.18, falling short of the consensus estimate of $2.42. The company expects fiscal 2015 sales to be $81...
newratings.com  Nov 6  Comment 
LONDON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) said that its partner GlaxoSmithKline plc. (GSK, GSK.L) reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade or eltrombopag,...
newratings.com  Oct 27  Comment 
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Monday said its third-quarter profit declined, as higher operating costs, especially from business development activities and stock-based compensation expense, eclipsed revenue growth....
Benzinga  Oct 17  Comment 
Rev. Emmanuel Lemelson is the chief investment officer of Lemelson Capital Management, an investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga’s #PreMarket Prep to talk about why he...
GenEng News  Oct 15  Comment 
Protein remains at the top of methodologies for capturing or otherwise isolating monoclonal antibodies from bioprocess streams. Although resins have much higher capacities and lower sensitivity to cleaning agents than a decade ago, issues of cost,...
SeekingAlpha  Oct 10  Comment 
By InsiderInsights: Dollar value is only one metric to assess the significance of an insider transaction, but when high dollar value intersects with significance it spotlights a stock investors should take the time to consider. InsiderInsights...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki